- AlmirallShare launches its fifth call for proposals, aiming to establish partnerships to find new assets—new chemical entities, biologics and other advanced therapies—for the treatment of dermatological conditions
- Scientists can participate until October 31, 2020
- AlmirallShare is responsible for 50% of the private-public collaborations at Almirall. This open innovation platform has received more than 350 proposals since its launch in 2017
AlmirallShare, the open innovation platform of Almirall, S.A. (ALM), launches its fifth call, aiming to establish collaborations in dermatological…
AMSBIO offers a comprehensive range of end-to-end services for exosome purification, characterization, and engineering.Exosomes are small endosome derived lipid nanoparticles, actively secreted by exocytosis in most living cells. Acting on tissues in both the local environment and further afield, they function as important signal carriers through their transport of RNA, proteins, lipids and DNA. Exosomes are involved in a wide range of normal and pathogenic processes, making exosome research crucial in multiple areas. Exosomes are a type of extracellular vesicle (EV) that show promise…
With the expansion of two of Biocair’s North American facilities, the company’s offerings in the US have increased substantially.
The Philadelphia office has doubled in size, with a state-of-the-art cryogenic filling station to further support cell and gene therapy clients, while the expanded Boston office will allow Biocair to improve delivery and service, with greater operational capacity.
Bruce Kennedy, Chief Commercial Officer, stated, “Biocair has always been strong in the US market, with offices in Los Angeles, New York, Raleigh Durham, San Diego, San Francisco and Washington as well as…
Cambridge, UK, 29 July 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today provides an unaudited pre-close trading update for the six months ended 30 June 2020. The Company plans to report its half year 2020 results on 17 August 2020.
Financials
Horizon expects to report half year 2020 revenues of approximately £22.4 million (HY 2019: £26.1 million, c. -13.9%)1,…
Westbury, NY – July 28, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it can now provide broader access to its growing inventory of plasma, serum and saliva specimens from active and recovered COVID-19 patients for use in drug, diagnostic and vaccine research.
“COVID-19 has already afflicted more than 16 million people and claimed more than 650,000 lives worldwide. It is a complex disease that demands the attention of the world’s best medical researchers. We are already working with more than 500 clients,…
Launched in 2018, Kao Data develop and operate advanced data centres for high performance computing. From our hyperscale inspired campus in the heart of the UK Innovation Corridor between London and Cambridge - we provide HPC, cloud, AI and enterprise customers with a world-class home for their compute.
We are proud to be sponsoring the Start-up of the Year Award at the 2020 Cambridge Independent Science and Technology Awards.
Spencer Lamb, vice president at Kao Data, says: “At Kao Data, we provide the infrastructure that underpins innovation – and so we are especially proud to be sponsoring…
A Newcastle-based pre-clinical service provider has been awarded Innovate UK grant to support the global fight against COVID-19.
Innovate UK, the UK’s innovation agency has awarded Alcyomics, £50,000 to carry out critical scientific support in the production of a vaccine for Covid-19.
They are one of three businesses that are based in The Biosphere that have received a share of the £40million government investment that was awarded to 800 applicants across the UK. Innovate UK received a record 8,600 applications from across the UK, with this Fast Start competition…
Used in combination with StemFit Basic feeder-free medium with iMatrix-511 laminin as extracellular matrix, StemFit® for Differentiation enables researchers to undertake clinical applications involving both expansion and differentiation of human Pluripotent Stem Cell-derived cells and tissues.Supplied as a 5X concentrate, StemFit® for Differentiation has been formulated for use with basal cell culture medium (e.g. DMEM, RPMI 1640, DMEM/F12 etc.) and a variety of different induction factors or cytokines (including Activin A and bFGF from AMSBIO).For further information on StemFit® for…
Norwich, UK – 21 July 2020: Leaf Expression Systems (Leaf), a contract development and manufacturing organisation specialising in plant-based expression of proteins, vaccines, enzymes and complex natural products, is pleased to announce the recent appointment of Dr. Leanne Williams as Business Development Manager. Leanne has over 10 years’ experience working in the life sciences industry in both commercial and academic settings and will lead the growth of Leaf’s pipeline by identifying and establishing commercial collaborations within the global life science industry.
Leanne holds a PhD in…